Florese Ruth H, Wiseman Roger W, Venzon David, Karl Julie A, Demberg Thorsten, Larsen Kay, Flanary Leon, Kalyanaraman V S, Pal Ranajit, Titti Fausto, Patterson L Jean, Heath Megan J, O'Connor David H, Cafaro Aurelio, Ensoli Barbara, Robert-Guroff Marjorie
Vaccine Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Vaccine. 2008 Jun 19;26(26):3312-21. doi: 10.1016/j.vaccine.2008.03.100. Epub 2008 Apr 30.
Protection afforded by HIV Tat-based vaccines has differed in Indian rhesus and Mauritian cynomolgus macaques. We evaluated native Tat and Ad-HIVtat priming/Tat-boosting regimens in both species. Both vaccines were immunogenic. Only the Ad-tat regimen modestly reduced acute viremia in rhesus macaques after SHIV(89.6P) challenge. Confounding variables uncovered in Mauritian macaques included significant associations of susceptibility to infection with MHC class IB and class II H2 and H5 haplotypes, and resistance to infection with class IB haplotypes H3 and H6. Although protection here was limited, Tat-based vaccines incorporating other HIV components have shown greater efficacy. Combination strategies should be further explored.
基于HIV反式激活因子（Tat）的疫苗在印度恒河猴和毛里求斯食蟹猴中提供的保护作用有所不同。我们评估了两种猴类中天然Tat以及腺病毒载体HIV Tat初免/Tat加强免疫方案。两种疫苗均具有免疫原性。在感染猿猴免疫缺陷病毒（SHIV，89.6P）后，只有腺病毒载体Tat方案适度降低了恒河猴的急性病毒血症。在毛里求斯猴中发现的混杂变量包括，感染易感性与MHC I类B基因以及II类H2和H5单倍型之间存在显著关联，而I类B基因单倍型H3和H6与抗感染性有关。尽管此处的保护作用有限，但包含其他HIV成分的基于Tat的疫苗已显示出更高的效力。应进一步探索联合策略。
